한글목차

세계 순환종양세포(CTC) 시장은 2024년 69억 6,000만 달러로 평가되었고, 예측 기간 동안 7.52%의 연평균 성장률(CAGR)로 성장하여 2030년에는 106억 3,000만 달러에 달할 것으로 예상됩니다.

이 시장은 암 조기 발견에 대한 수요 증가, 개인 맞춤형 의료의 확산, 액체생검 기술의 큰 발전에 힘입어 큰 폭으로 성장하고 있습니다.

원발성 종양에서 떨어져 나와 혈류를 타고 이동하는 암세포인 순환 종양세포(CTC)는 암의 진행과 전이 위험을 평가하는 중요한 바이오마커로, CTC를 검출하고 분석할 수 있게 됨에 따라 암 진단과 치료 모니터링의 형태가 바뀌고 있으며, 이러한 기술은 진화하는 종양학 상황에서 핵심적인 도구가 되고 있습니다. 진화하는 종양학 상황에서 중심적인 도구가 되고 있습니다.

주요 시장 성장 촉진요인

세계 헬스케어 산업의 확장

주요 시장 이슈

CTC 기반 기술에 따른 높은 비용

주요 시장 동향

비침습적 진단 솔루션 채택 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 순환종양세포(CTC) 시장에 미치는 영향

제5장 세계의 순환종양세포(CTC) 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 제품별(키트 및 시약, 채혈관, 디바이스 또는 시스템)
  • 기술별(CTC 감지 및 농축법, CTC 직접 감지법, CTC 분석)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 순환종양세포(CTC) 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 순환종양세포(CTC) 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 순환종양세포(CTC) 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 순환종양세포(CTC) 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 순환종양세포(CTC) 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)
• 제품 출시
• 최근 동향

제13장 세계의 순환종양세포(CTC) 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• QIAGEN N.V.
• Bio-Techne Corp.
• Precision Medicine Group, LLC
• Bio-Rad Laboratories, Inc.
• Natera, Inc.
• Illumina, Inc.
• Greiner Bio-One International GmbH
• Ikonisys Inc.
• Creative Bioarray
• Abnova Corporation

제16장 전략적 제안

제17장 리서치사에 대해 & 면책사항

영문목차

Global circulating tumor cells (CTCs) market was valued at USD 6.96 billion in 2024 and is projected to reach USD 10.63 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.52% during the forecast period. The market is experiencing substantial growth, fueled by increasing demand for early cancer detection, the expanding adoption of personalized medicine, and significant advancements in liquid biopsy technologies.

Circulating tumor cells-cancerous cells that detach from primary tumors and enter the bloodstream-serve as crucial biomarkers for assessing cancer progression and the risk of metastasis. The ability to detect and analyze CTCs has reshaped cancer diagnostics and treatment monitoring, positioning these technologies as central tools in the evolving landscape of oncology.

Key Market Drivers

Expansion of the Global Healthcare Industry

The expansion of the global healthcare industry is playing a pivotal role in propelling the CTCs market forward. In response to the growing global cancer burden, institutions like the World Health Organization (WHO) have introduced initiatives such as the Guide to Cancer Early Diagnosis, which promotes timely detection and improved access to cancer care.

Healthcare systems are increasingly embracing precision medicine and early detection strategies to improve patient outcomes and reduce long-term treatment costs. CTCs offer a non-invasive and dynamic approach to cancer diagnostics by enabling the real-time tracking of tumor evolution, therapeutic response, and metastatic spread. Their ability to reveal the molecular characteristics of tumors makes them indispensable tools for guiding targeted therapy development and implementation.

The global rise in cancer prevalence further intensifies the need for efficient diagnostic tools. CTC-based technologies provide actionable insights that support the development of individualized treatment plans, making them a key component in the global push toward more precise and effective cancer care.

Key Market Challenges

High Costs Associated with CTC-Based Technologies

Despite their clinical benefits, CTC-based diagnostic technologies face challenges related to high implementation costs. Isolating and identifying circulating tumor cells-present in extremely low concentrations in the bloodstream-requires advanced equipment, including microfluidic devices, high-resolution imaging platforms, and sensitive molecular analysis tools. These systems are not only expensive to develop but also to deploy and maintain, making widespread clinical adoption difficult, particularly in cost-sensitive or resource-constrained healthcare environments. Beyond the cost of testing, substantial research and development (R&D) investments are needed to improve sensitivity, accuracy, and scalability of these technologies.

Key Market Trends

Rising Adoption of Non-Invasive Diagnostic Solutions

An increasing shift toward non-invasive diagnostics represents a significant trend shaping the global CTCs market. As healthcare providers and patients seek safer, faster, and more convenient alternatives to traditional biopsies, liquid biopsy solutions based on CTC detection are gaining momentum.

Liquid biopsy, enabled by a simple blood draw, allows for repeated, real-time monitoring of tumor dynamics without the discomfort or risks associated with tissue biopsies. This has led to the development and approval of tests such as the CellSearch Circulating Tumor Cell (CTC) Test, which is FDA-approved for assessing prognosis in patients with metastatic breast, prostate, or colorectal cancers. A low CTC count is associated with a more favorable outlook, while a high count may signal disease progression.

As this technology matures, liquid biopsy is becoming a cornerstone of precision oncology, offering dynamic insights into treatment effectiveness, disease progression, and early recurrence-all without disrupting patient comfort. This trend is fundamentally transforming how cancer is diagnosed and managed, driving the demand for innovative, non-invasive CTC-based diagnostics across global markets.

Key Market Players

• QIAGEN N.V.
• Bio-Techne Corp.
• Precision Medicine Group, LLC
• Bio-Rad Laboratories, Inc.
• Natera, Inc.
• Illumina, Inc.
• Greiner Bio-One International GmbH
• Ikonisys Inc.
• Creative Bioarray
• Abnova Corporation

Report Scope

In this report, the Global Circulating Tumor Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Circulating Tumor Cells Market, By Product:

• Kits & Reagents
• Blood Collection Tubes
• Devices or Systems

Circulating Tumor Cells Market, By Technology:

• CTC Detection & Enrichment Methods
• CTC Direct Detection Methods
• CTC Analysis

Circulating Tumor Cells Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Circulating Tumor Cells Market.

Available Customizations:

Global Circulating Tumor Cells Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Circulating Tumor Cells Market

5. Global Circulating Tumor Cells Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Kits & Reagents, Blood Collection Tubes, Devices or Systems)
  • 5.2.2. By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Circulating Tumor Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Circulating Tumor Cells Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
  • 6.3.2. Mexico Circulating Tumor Cells Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
  • 6.3.3. Canada Circulating Tumor Cells Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology

7. Europe Circulating Tumor Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Circulating Tumor Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
  • 7.3.2. Germany Circulating Tumor Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
  • 7.3.3. United Kingdom Circulating Tumor Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
  • 7.3.4. Italy Circulating Tumor Cells Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
  • 7.3.5. Spain Circulating Tumor Cells Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology

8. Asia Pacific Circulating Tumor Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Circulating Tumor Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
  • 8.3.2. India Circulating Tumor Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
  • 8.3.3. South Korea Circulating Tumor Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
  • 8.3.4. Japan Circulating Tumor Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
  • 8.3.5. Australia Circulating Tumor Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology

9. South America Circulating Tumor Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Circulating Tumor Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
  • 9.3.2. Argentina Circulating Tumor Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
  • 9.3.3. Colombia Circulating Tumor Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology

10. Middle East and Africa Circulating Tumor Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Circulating Tumor Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
  • 10.3.2. Saudi Arabia Circulating Tumor Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
  • 10.3.3. UAE Circulating Tumor Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Circulating Tumor Cells Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. QIAGEN N.V.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Bio-Techne Corp.
• 15.3. Precision Medicine Group, LLC
• 15.4. Bio-Rad Laboratories, Inc.
• 15.5. Natera, Inc.
• 15.6. Illumina, Inc.
• 15.7. Greiner Bio-One International GmbH
• 15.8. Ikonisys Inc.
• 15.9. Creative Bioarray
• 15.10. Abnova Corporation

16. Strategic Recommendations

17. About Us & Disclaimer